Sobi KOL investor event: the journey for Vonjo®

19 July 2023 15:30 CEST, 14:30 BST, 09:30 EDT Following the completion of Sobi’s acquisition of CTI Biopharma, Sobi’s management will host a virtual KOL event. Sarah Buckley, VP and Head of Clinical Affairs at CTI Biopharma, and Key Opinion Leader, Dr John Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, will discuss the clinical and commercial opportunity of CTI Biopharma’s lead asset, Vonjo (pacritinib). The presentation can be followed live here or afterwards on sobi.com. To participate in the conference call, please use the following dial-in details: Sweden: +46 8 5051 0031 United Kingdom: +44 207 107 06 13 United States: +1 631 570 56 13 For other countries, please get details here Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube . Contacts For details on how to contact the Sobi Investor Relations Team, please click here . For Sobi Media contacts, click here .

The release as fetched from its publisher. sobi.com ↗